What Happened?

About the Company

Regenxbio is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. Regenxbio`s NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. Regenxbio`s mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on Regenxbio`s NAV Technology Platform. Regenxbio seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees.

About the Person